{"brief_title": "A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients", "brief_summary": "To determine the maximum tolerated dose of CI-1012 in late-stage HIV-1-infected patients. To determine the antiretroviral activity of CI-1012 when added to combination therapy. To assess the multiple-dose pharmacokinetic characteristics of CT-1012 when added to combination therapy. To assess the effect of CI-1012 on the pharmacokinetics of other antiretroviral agents.", "detailed_description": "Doses are escalated based on safety assessments: As soon as a dose meets the criteria for \"tolerated\" or \"not tolerated\", doses are escalated or terminated, respectively. All patients are treated for 2 weeks, with follow-up visits scheduled 1 week and 1 month post-treatment.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "CI-1012", "criteria": "Inclusion Criteria Patients must have: - Serological evidence of late-stage HIV-1 infection (ELISA and Western Blot). - CD4 T cell count less than or equal to 200 mm3. - HIV-1 RNA greater than or equal to 5,000 copies/mL. Exclusion Criteria Prior Medication: Excluded: - Anti-HIV treatment within 8 weeks prior to entry. - Systemic steroids within 4 weeks prior to entry. Prior Treatment: Excluded: Treatment with anticancer agents within 4 weeks prior to study.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002218.xml"}